Patient Types for Acthar
Some patients need an alternative to IV steroids
Consider Acthar when your patients...
- Have poor venous access
- Express tolerability concerns with IV steroids
- Report an inadequate response to IV steroids
- Need the flexibility of a selfinjection at home or work
Acthar is an effective, flexible treatment option
- Proven efficacy for patients with MS exacerbations[1][2][3][4]
- Conveniently delivered via self-administered injection[1]
- Stimulates the adrenal cortex to secrete the body's natural steroids[1]
Acthar (repository corticotropin injection) is indicated for the treatment of acute exacerbations in patients with multiple sclerosis, for the diagnosis of adrenocortical function, and for several other uses.
References
- ^ H.P. Acthar® Gel (repository corticotropin injection), prescribing information, Questcor Pharmaceuticals, Inc.
- ^ Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology. 1989;39:969-971.
- ^ Rose AS, Kuzma JW, Kurtzke JF, et al. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo-final report. Neurology. 1970:20:1-59.
- ^ Milanese C, La Mantia L, Salmaggi A, et al. Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Eur Neurol. 1989;29:10-14.